Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 Combination Therapy in Platinum-Sensitive Ovarian Cancer
NCT06686030Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in ovarian cancer, sponsored by Akeso, Inc.. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06686030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686030.